ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Pyruvate dehydrogenase kinase 1 (PDHK1) was inhibited by DCA and DCA-expanded T cells showed a highly varied metabolome, higher mitochondrial mass, and altered mitochondrial physiology.

Center for Structural Biology of Infectious Diseases, Consortium for Advanced Science and Engineering, University of Chicago, Chicago, Illinois 60667, United States The Structural Biology Center, ...

DCA is a targeted therapy that inhibits Pyruvate Dehydrogenase Kinase (PDK) to stimulate residual Pyruvate Dehydrogenase Complex (PDC) activity and increase energy (ATP) production by mitochondria.

Moreover, 3.6 mM βHB induced the disruption of the pyruvate dehydrogenase (PDH) activity, showing with the decrease of the ... that the potential negative effects of βHB were mediated by oxidative ...

Here, we demonstrate that pyruvate dehydrogenase kinase (PDK), which inhibits the pyruvate dehydrogenase ... Genetic deletion or pharmacological inhibition of PDK2/4 prevents polarization of ...